Leerink Partnrs Equities Analysts Increase Earnings Estimates for Applied Therapeutics, Inc. (NASDAQ:APLT)

Applied Therapeutics, Inc. (NASDAQ:APLT) – Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings estimates for shares of Applied Therapeutics in a report released on Wednesday, September 18th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.14) per share for the quarter, up from their previous forecast of ($0.15). The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Applied Therapeutics’ Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.36) EPS and FY2026 earnings at ($0.25) EPS.

Several other analysts have also issued reports on the company. William Blair upgraded Applied Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Citigroup increased their price objective on shares of Applied Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $12.00 price target on shares of Applied Therapeutics in a report on Wednesday, July 17th. Finally, Leerink Partners increased their target price on Applied Therapeutics from $11.00 to $14.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Applied Therapeutics has an average rating of “Buy” and a consensus target price of $12.50.

Applied Therapeutics Price Performance

Shares of APLT opened at $8.11 on Monday. The firm has a 50-day moving average of $5.89 and a 200-day moving average of $5.34. The company has a market cap of $926.13 million, a PE ratio of -4.40 and a beta of 2.03. Applied Therapeutics has a one year low of $1.79 and a one year high of $9.39.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.03). The business had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $10.00 million.

Insiders Place Their Bets

In related news, CEO Shoshana Shendelman sold 119,591 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $5.93, for a total value of $709,174.63. Following the transaction, the chief executive officer now owns 4,690,839 shares in the company, valued at $27,816,675.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 8.60% of the company’s stock.

Institutional Trading of Applied Therapeutics

Several large investors have recently bought and sold shares of the business. Principal Financial Group Inc. bought a new position in Applied Therapeutics in the 2nd quarter valued at approximately $54,000. Victory Capital Management Inc. acquired a new stake in shares of Applied Therapeutics in the second quarter valued at about $54,000. Jump Financial LLC acquired a new position in shares of Applied Therapeutics in the fourth quarter worth approximately $81,000. SG Americas Securities LLC acquired a new stake in Applied Therapeutics during the 2nd quarter valued at approximately $87,000. Finally, Algert Global LLC acquired a new stake in shares of Applied Therapeutics during the second quarter worth $110,000. 98.31% of the stock is owned by institutional investors and hedge funds.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.